Siponimod is a drug from the sphingosine-1-phosphate receptor modulator family, used in the treatment of multiple sclerosis. It was approved in March 2019 for the treatment of patients with relapsing forms of the pathology. Its use requires prior genetic analysis in some cases, due to hepatic metabolism dependent on CYP2C9.
Siponimod (Dosage)
Siponimod is an immunomodulatory drug used to treat active secondary progressive multiple sclerosis (SPMS). It acts as a selective modulator of sphingosine-1-phosphate receptors (S1P1 and S1P5), which helps reduce the migration of lymphocytes to the central nervous system and decrease inflammation and neuronal damage.
MECHANISM OF ACTION
Siponimod is a selective modulator of sphingosine 1-phosphate receptors on lymphocytes. By acting as a functional antagonist of these receptors, the drug prevents lymphocytes from exiting the lymph nodes, reducing the recirculation of these cells in the central nervous system and limiting central inflammation.
Siponimod is indicated for the treatment of adults with secondary progressive multiple sclerosis with active disease, with relapses or intense inflammatory activity.
CONTRAINDICATIONS
Treatment with siponimod is contraindicated in patients with hypersensitivity to the drug or any of its components, immunodeficiency syndrome, history of meningitis or leukoencephalopathy, cancer, liver failure, recent stroke, and during pregnancy.
SIDE EFFECTS
The most frequently reported, although infrequent, side effects are dizziness, pain in the arms, legs, hands or feet, diarrhea, and headache. Some of the side effects can be serious, such as slow heart rate, vomiting, fever, stiff neck, sudden and severe headache, difficulty breathing, vomiting, or swelling in the hands, among others.
Siponimod may also increase the risk of developing skin cancer, so patients taking it should examine their skin before and during treatment to detect changes.
INTERACTIONS
Although the use of siponimod in combination with other neoplastic or immunomodulatory treatments has not been studied, caution should be exercised during concomitant administration due to the risk of additive effects.
The use of siponimod is contraindicated with some antiarrhythmic treatments, calcium channel antagonists, or other compounds that decrease heart rate. Caution should also be taken with taking beta-blocker medications.
During treatment with siponimod and for 4 weeks after its discontinuation, the administration of live attenuated microorganism vaccines should be avoided.
TRADE NAMES
- Mayzent®
Genes analyzed
Bibliography
Díaz-Villamarín X, Piñar-Morales R, et al. Pharmacogenetics of siponimod: A systematic review. Biomed Pharmacother. 2022 Sep;153:113536.
Kane M. Siponimod Therapy and CYP2C9 Genotype. 2023 Aug 9. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US).
